The Human Medicines Regulations 2012
5 Marketing authorisations
- 49Application for grant of UK marketing authorisation or parallel import licence
- 50Accompanying material
- 50aRequirement for certain applications to include results of paediatric investigation plan
- 50bAgreement and modification of paediatric investigation plan
- 50cDeferral of initiation or completion of measures in paediatric investigation plan
- 50dWaiver of production of information in a paediatric investigation plan
- 50eApplication for paediatric use marketing authorisation
- 50fOther applications including paediatric indications
- 50gApplications relating to orphan medicinal products
- 50hApplications relating to advanced therapy medicinal products
- 50iApplications relating to conditional marketing authorisations …
- 50jApplications in relation to medicinal products containing or consisting of genetically modified organisms
- 50kApplications relating to POC medicinal products
- 51Application for UKMA(NI) relating to generic medicinal products
- 51aApplication for UKMA(GB) relating to generic medicinal products
- 51bApplication for UKMA(UK) relating to generic medicinal products
- 52Application for UKMA(NI) relating to certain medicinal products that do not qualify as generic etc
- 52aApplication for UKMA(GB) relating to certain medicinal products that do not qualify as generic etc
- 52bApplication for UKMA(UK) relating to certain medicinal products that do not qualify as generic etc.
- 53Application for UKMA(NI) relating to similar biological medicinal products
- 53aApplication for UKMA(GB) relating to similar biological medicinal products
- 53bApplication for UKMA(UK) relating to similar biological medicinal products
- 54Applications relating to products in well-established medicinal use
- 55Applications relating to new combinations of active substances
- 56Applications containing information supplied in relation to another product with consent
- 57Obligation to update information supplied in connection with application
- 57aObligation to update information supplied in connection with parallel import licence application
- 58Consideration of application
- 58aPaediatric rewards
- 58bPublication of information relating to paediatric marketing authorisations
- 58cConsideration of applications relating to orphan medicinal products
- 58dOrphan rewards
- 58eConsideration of applications relating to combined advanced therapy medicinal products
- 58fConsideration of applications relating to conditional marketing authorisations
- 58gConsideration of applications in relation to medicinal products containing or consisting of genetically mo
- 59Conditions of UK marketing authorisation or parallel import licence: general
- 60Conditions of UK marketing authorisation or parallel import licence: exceptional circumstances
- 60aCondition as to the submitting of samples and other information to the appropriate authority
- 60bSubmitting of samples and other information: EU marketing authorisations
- 61Conditions of UK marketing authorisation: new obligations post-authorisation
- 62Classification of UK marketing authorisation or parallel import licence
- 63Frequency of periodic safety update reports
- 64Duties of licensing authority in connection with determination
- 64aObligation of licensing authority in case of change of classification
- 65Validity of UK marketing authorisation
- 65aValidity of parallel import licence
- 65bValidity of conditional marketing authorisation
- 65cVariation of a UKMA(GB) or a UKMA(UK)(Category 1)
- 66Application for renewal of authorisation
- 66aApplication for renewal of a parallel import licence
- 66bRenewal of conditional marketing authorisation
- 67Failure to place on the market etc
- 68Revocation, variation and suspension of UK marketing authorisation or parallel import licence
- 69Suspension of use etc of relevant medicinal product
- 70Authorisations granted under Chapter 4 of Title III of the 2001 Directive
- 71Withdrawal of medicinal product from the market
- 72Sale etc of suspended medicinal product
- 73Obligation to notify placing on the market etc
- 74Obligation to take account of scientific and technical progress
- 74aObligation to provide information relating to methods of manufacture and control: MM medicinal products
- 74bObligation to provide information relating to methods of manufacture and control: POC medicinal products
- 75Obligation to provide information relating to safety etc
- 76Obligation in relation to product information
- 77Record-keeping obligations
- 78Obligation to ensure appropriate and continued supplies
- 78aPost authorisation requirements in relation to UK marketing authorisations to which paediatric specific pr
- 78bPost authorisation requirements in relation to UKMA(UK)(Category 1) for advanced therapy medicinal product
- a81Application of regulations 89 to 94
- 81Obligation to update information supplied in connection with EU application
- 82EU marketing authorisations: failure to notify placing on market etc
- 83EU marketing authorisations: failure to take account of technical and scientific progress
- 84EU marketing authorisations: failure to provide information as to safety etc
- 85EU marketing authorisations: failure to update product information
- 86EU marketing authorisations: breach of pharmacovigilance condition etc
- 89Offences in connection with withdrawal of product from the market
- 90Failure to place on the market taking account of paediatric indication
- 91Failure to notify results of third country clinical trials
- 92Failure of sponsor of UK paediatric clinical trial to notify results of trial
- 93Failure to notify results of paediatric study
- 94Failure to submit report to EMA
Source: legislation.gov.uk (The National Archives), UK legislation with its point-in-time versions. Official publication. Reuse: Open Government Licence v3.0.